Eflapegrastim
Eflapegrastim is a once-per-cycle white cell growth factor approved in the United States in 2022 to prevent infections when chemotherapy for solid tumours knocks down neutrophils, an alternative to pegfilgrastim.
Overview
Eflapegrastim uses Hanmi's long-acting carrier technology to extend the life of G-CSF. The FDA approved it in September 2022 to decrease the incidence of febrile neutropenia in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy, after the ADVANCE and RECOVER trials showed it was non-inferior to pegfilgrastim for the duration of severe neutropenia in breast cancer patients on docetaxel and cyclophosphamide. It is given about 24 hours after chemotherapy; bone pain and nausea are the common side effects. It was developed by Spectrum Pharmaceuticals and is now marketed by Assertio.
G-CSF joined to an IgG4 Fc fragment through a polyethylene glycol linker, so it is cleared slowly and keeps stimulating neutrophil production for the whole cycle. Connects to G-CSF receptor (CSF3R).
1.Eflapegrastim binds G-CSF receptor (CSF3R).
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2022 | To decrease the incidence of febrile neutropenia in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Eflapegrastim" OR ABSTRACT:"Eflapegrastim" OR TITLE:"Rolvedon" OR ABSTRACT:"Rolvedon" OR TITLE:"Eflapegrastim-xnst" OR ABSTRACT:"Eflapegrastim-xnst" OR TITLE:"SPI-2012" OR ABSTRACT:"SPI-2012") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Eflapegrastim, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentLenograstim
Shares G-CSF receptor (CSF3R), Pegfilgrastim, Cytokines & engineered cytokines and the tag chembl-universe.
- TreatmentPeginterferon alfa-2b
Shares Cytokines & engineered cytokines and the tag chembl-universe.
- TreatmentOprelvekin
Shares Cytokines & engineered cytokines and the tag chembl-universe.
- TreatmentSargramostim
Shares Cytokines & engineered cytokines and the tag chembl-universe.
- TreatmentTechnetium Tc-99m sulfur colloid
Shares HR-positive / HER2-negative breast cancer and the tag chembl-universe.
- TreatmentFluoxymesterone
Shares HR-positive / HER2-negative breast cancer and the tag chembl-universe.
- TreatmentDiethylstilbestrol
Shares HR-positive / HER2-negative breast cancer and the tag chembl-universe.
- TreatmentFormestane
Shares HR-positive / HER2-negative breast cancer and the tag chembl-universe.